Paul Dillon

Roche (Switzerland) — Switzerland

Medicine · Health Sciences

25h-index4.3kcitations105works8.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(15), Forensic Toxicology and Drug Analysis(15), Substance Abuse Treatment and Outcomes(12), Cancer, Hypoxia, and Metabolism(12), Medication Adherence and Compliance(12)

Publications105 total

Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment
PharmacoEconomics - Open·2024· 8 citedOpen Access
Educating students about volatile substance use in <scp>Australian</scp> schools: Is the current approach evidence‐based, and how should we do it?
Health Promotion Journal of Australia·2023· 1 citedOpen Access
The socioeconomic impact of disability progression in multiple sclerosis: A retrospective cohort study of the German NeuroTransData (NTD) registry
Multiple Sclerosis Journal - Experimental Translational and Clinical·2023· 10 citedOpen Access
Factorial survey methodology to inform pharmacy adherence interventions: comparison of two international studies
Research in Social and Administrative Pharmacy·2023
Data from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023· 1 citedOpen Access
Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023Open Access
Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023Open Access
Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023Open Access
Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023Open Access
Data from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023Open Access
Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023Open Access
Supplementary Figure from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023Open Access
Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023Open Access
Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023Open Access
Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023Open Access
Supplementary Figure from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023Open Access
Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023Open Access
Supplementary Table from Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
2023Open Access
Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis
Multiple Sclerosis and Related Disorders·2023· 4 citedOpen Access
Table of Contents
Journal of the American Pharmacists Association·2022Open Access
page 1 of 6Next →

Frequent Co-authors

Jan Copeland(18), Louisa Degenhardt(7), Richard Peters(6), Susan M. Smith(6), Paul Gallagher(6), Peter Gates(5), Gráinne Cousins(5), Briony Larance(3), Erwan Muros‐Le Rouzic(3), Sunder Mudaliar(2), Linda Morrow(2), Mark Kipnes(2), Paul Clopton(2), Д. А. Шапиро(2), Mark A Bellis(2), Karen Hughes(2), Libby Topp(2), Julie Hando(2), Wendy Swift(2), Shane Darke(2)